What is pembrolizumab (Keytruda) and is it used for MDS

Q: What is pembrolizumab (Keytruda) and is it used for MDS

Pembrolizumab is a type of immunotherapy drug called a checkpoint inhibitor. Here's how it works in plain language: Your immune system has "brakes" that prevent it from attacking your own cells. Cancer cells sometimes hijack these brakes to hide from your immune system. Pembrolizumab works by releasing these brakes, essentially telling your immune system: "This is cancer—attack it." By removing this "off switch," the drug helps your body's own T cells recognize and destroy cancer cells. Current

MDSMay 17, 2026Navis AI

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Pembrolizumab (Keytruda) and MDS: What You Should Know

What is Pembrolizumab?

Pembrolizumab is a type of immunotherapy drug called a checkpoint inhibitor. Here's how it works in plain language:

Your immune system has "brakes" that prevent it from attacking your own cells. Cancer cells sometimes hijack these brakes to hide from your immune system. Pembrolizumab works by releasing these brakes, essentially telling your immune system: "This is cancer—attack it." By removing this "off switch," the drug helps your body's own T cells recognize and destroy cancer cells.

Use in MDS: Limited but Growing

Current FDA Status: Pembrolizumab is not FDA-approved as a standard treatment for MDS. However, it has shown promise in specific MDS situations and is being studied actively.

Where It May Be Used:

According to NCCN Guidelines for Myelodysplastic Syndromes, pembrolizumab may be considered in certain circumstances:

Patients with high PD-L1 expression (a marker suggesting the cancer is hiding from the immune system)
As part of clinical trials for MDS patients
In select cases where other standard treatments haven't worked

More Common MDS Treatments: The standard first-line approaches for MDS typically include:

Hypomethylating agents (azacitidine, decitabine)
Lenalidomide (for specific genetic mutations)
Supportive care (transfusions, growth factors)

Questions to Ask Your Doctor

If your oncologist mentions pembrolizumab for your MDS:

Do I have the specific characteristics that make pembrolizumab appropriate for my MDS? (such as PD-L1 status or specific mutations)
Is this being offered as part of a clinical trial, or as an off-label treatment?
What are the expected benefits and side effects compared to other options for my situation?
What is the evidence supporting this approach for my specific MDS subtype?
Are there other standard treatments we should consider first?